Therapy assessment of bone metastatic disease in the era of 223radium

Therapy assessment of bone metastatic disease in the era of 223radium Eur J Nucl Med Mol Imaging (2017) 44 (Suppl 1):S84–S96 DOI 10.1007/s00259-017-3734-0 REVIEW ARTICLE Therapy assessment of bone metastatic disease in the era of radium 1 1 2 2 Elba Etchebehere & Ana Emilia Brito & Alireza Rezaee & Werner Langsteger & 2,3 Mohsen Beheshti Received: 10 May 2017 /Accepted: 12 May 2017 /Published online: 31 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract Introduction Purpose Defining an optimal imaging modality for assess- ment of therapy and the best time of evaluation are pivotal Prostate cancer is the second most common cancer among for ideal patient’smanagement. men and the sixth leading cause of cancer-related death world- Methods Ra (Xofigo®, formerly Alpharadin) has been ap- wide [1]. It metastasizes to skeleton in approximately 65–75% proved by the FDA and European Medicines Agency for treat- of cases, which dramatically changes the outcome in these ment of metastatic castration-resistant prostate cancer with patients [2, 3]. To avoid related morbidities such as bone pain, painful osseous involvement. bone fracture and possible cord compression, it is crucial to Results PET/CT imaging using various radiotracers such as discover and manage the lesions early in the course of meta- 18 18 68 18 F–FDG, F–FCH, Ga-PSMA and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Nuclear Medicine and Molecular Imaging Springer Journals

Therapy assessment of bone metastatic disease in the era of 223radium

Loading next page...
 
/lp/springer_journal/therapy-assessment-of-bone-metastatic-disease-in-the-era-of-223radium-yB6lv4w6eP
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1619-7070
eISSN
1619-7089
D.O.I.
10.1007/s00259-017-3734-0
Publisher site
See Article on Publisher Site

Abstract

Eur J Nucl Med Mol Imaging (2017) 44 (Suppl 1):S84–S96 DOI 10.1007/s00259-017-3734-0 REVIEW ARTICLE Therapy assessment of bone metastatic disease in the era of radium 1 1 2 2 Elba Etchebehere & Ana Emilia Brito & Alireza Rezaee & Werner Langsteger & 2,3 Mohsen Beheshti Received: 10 May 2017 /Accepted: 12 May 2017 /Published online: 31 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract Introduction Purpose Defining an optimal imaging modality for assess- ment of therapy and the best time of evaluation are pivotal Prostate cancer is the second most common cancer among for ideal patient’smanagement. men and the sixth leading cause of cancer-related death world- Methods Ra (Xofigo®, formerly Alpharadin) has been ap- wide [1]. It metastasizes to skeleton in approximately 65–75% proved by the FDA and European Medicines Agency for treat- of cases, which dramatically changes the outcome in these ment of metastatic castration-resistant prostate cancer with patients [2, 3]. To avoid related morbidities such as bone pain, painful osseous involvement. bone fracture and possible cord compression, it is crucial to Results PET/CT imaging using various radiotracers such as discover and manage the lesions early in the course of meta- 18 18 68 18 F–FDG, F–FCH, Ga-PSMA and

Journal

European Journal of Nuclear Medicine and Molecular ImagingSpringer Journals

Published: May 31, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off